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Objective: To investigate the association between activity during interferon beta 
therapy (IFN) and disability outcomes in patients with relapsing–remitting 
multiple sclerosis (RRMS).  
Methods: A longitudinal study based on two previously described cohorts of 
IFN treated RRMS patients was conducted. Patients were classified according 
to clinical activity after 2 years (clinical cohort) or to clinical and radiological 
activity after one year (MRI cohort).  Multivariate Cox models were calculated 
for early disease activity predicting long-term disability. 
Results: A total of 516 patients from two different cohorts were included in the 
analyses. Persistent clinical disease activity during the first 2 years of therapy 
predicted severe long-term disability (clinical cohort). In the MRI cohort, 
Modified Rio score, and no or minimal evidence of disease activity (NEDA / 
MEDA) did not identify patients with risk of EDSS worsening. However a Rio 
score ≥2 (HR 3.3 95% CI 1.7-6.4), ≥3 new T2 lesions (HR 2.9 95% CI 1.5-5.6) 
or ≥2 Gd-enhancing lesions (HR 2.1 95% CI 1.1-4) were able to identify patients 
with EDSS worsening.  
Conclusions: Although early activity during IFN therapy is associated with 
poor long-term outcomes, minimal degree of activity does not seem to be 







Interferon beta (IFN) has been demonstrated to reduce clinical and radiological 
activity (1-6). However, in the last years, new therapeutic approaches for the 
management of MS have appeared. In this scenario, it will be necessary to 
obtain early factors that predict long-term outcomes with the objective of 
optimizing therapy and of facilitating evidence-based therapeutic decision-
making (7).  
 
Studies have shown a positive association between early clinical and 
radiological activity during treatment with IFN and short- and long-term 
disability (8-16). In previous work, we demonstrated that isolated clinical activity 
during the first two years of treatment with IFN was predictive of an increase in 
disability after six years of follow-up (17), and we subsequently described an 
association between clinical and radiological activity during the first year of 
treatment with IFN and the presentation of new activity in the next two years 
(12). Thus, the combination of clinical and radiological measures seems to be 
the best strategy for predicting IFN treatment outcomes. Several scores that 
combine clinical and MRI markers have been proposed (12, 13, 18, 19, 20). 
However, these scoring systems have been tested only over short follow-up 
periods, and their long-term predictive value is currently unknown. 
 
Therefore, based on the above premises, the objectives were the following: 1) 
to evaluate the impact of early activity on long-term disease evolution in treated 
patients and 2) to compare the predictive value of different treatment monitoring 
scoring systems including the Rio score, modified Rio score, no or minimal 
evidence of disease activity (NEDA or MEDA), to identify which patients will 
attain clinically meaningful disability outcomes in the long term.  
 
Patients and Methods 
Study design and patient disposition 
This was a single-centre, longitudinal, observational study based on two 
previously described prospective cohorts of patients with MS who had received 
IFN (Figure 1). All patients were fully naive of any disease modifying drugs 
before starting IFN (12, 17). Our first cohort (clinical cohort) included patients 
treated with IFN between 1995 and 2001. The second cohort (clinical and MRI 
cohort, for ease termed the MRI cohort from here on) included patients who 
began IFN between 2001 and 2005. The reason for studying these two 
consecutive cohorts separately lies in the different monitoring protocols. For the 
first and oldest cohort, no MRI data were available. In contrast, in the second 
cohort, MRI data were obtained. The local ethical committee approved the 
study, and all patients provided their informed consent.  
 
Measures of early disease activity during treatment 
In the clinical cohort, based on a previous study (17), we defined a number of 
clinical activity measures during the first two years of treatment (17) (Figure 1). 
In that study, we demonstrated that EDSS worsening, the presence of relapses, 
and the combination of both measures in the first two years of therapy were 
significant predictors of irreversible disability after 6 years of follow-up, 
displaying very good specificity and sensitivity. Therefore, in the present study, 
we tested the value of the same measures to predict long-term disability. As 
previously described (17), an increase in the EDSS score after the first 2 years 
of treatment was defined as an EDSS worsening of at least 1 point confirmed at 
6 months and sustained up to the end of follow-up. If the EDSS score was 0 at 
baseline, an increase was defined as an EDSS score change of 1.5 or more, 
while a change in the EDSS score of 0.5 was defined as an increase in patients 
with scores greater than 5.0. Neurologists trained in EDSS scoring performed 
neurological assessments. A relapse was defined as the occurrence, 
recurrence or worsening of symptoms of neurological dysfunction lasting more 
than 24 hours and then stabilizing or eventually resolving either partially or 
completely.  
In the MRI cohort, patients were classified according to their clinical and MRI 
activity in the first year of therapy (12) (Figure 1). We considered activity after 
one year based on the following: the presence of relapses, sustained EDSS 
worsening, and new T2 or gadolinium (Gd)-enhancing lesions. Different scores 
were assigned and analysed according to different combinations of these 
measures of activity (11-14, 18), namely, the Rio score (RS), modified Rio score 
(MRS), and no evidence of disease activity (NEDA) scale score. The RS was 
obtained after the first year of therapy as follows: (i) MRI criterion, 1 point for 
patients with ≥3 new T2 and/or Gd-enhancing lesions; (ii) relapse criterion, 1 
point for patients with ≥1 relapse; and (iii) EDSS criterion, 1 point for patients 
with an EDSS score increase of ≥1 point, sustained at the end of follow-up. The 
MRS was obtained after the first year of therapy as follows: (i) MRI criterion, 1 
point for patients with ≥5 new T2 lesions and (ii) relapse criterion, 1 point for 
patients experiencing 1 relapse and 2 points for patients experiencing ≥2 
relapses. A total score (0–3) was calculated for each scoring system, and 
patients were classified into one of two categories: low (score 0–1) or high 
(score 2–3) risk. NEDA was defined as the absence of relapses, lack of EDSS 
worsening, and absence of MRI activity (new T2 or Gd-enhancing lesions). As 
NEDA aims to predict good evolution on therapy and the RS and MRS are 
scores aimed at predicting poor evolution on therapy, the term EDA (any 
evidence of disease activity) has been used to enable comparison between 
scores.  
Long-term disability outcomes 
Considering the different follow-up periods, i.e., 12 years for the clinical cohort 
and 8 years for the MRI cohort, we established different long-term outcomes for 
the two cohorts.  
For the clinical cohort after the first two years of treatment, we established the 
following outcomes: A) developing secondary progressive MS (SPMS), B) 
attaining a confirmed EDSS score of 7.5, and C) exhibiting an increase of at 
least 5 EDSS steps at the end of follow-up EDSS at month 24 was used as the 
starting point to evaluate progression. We defined progressive disease as a 
continuing deterioration (for at least one year) without substantial remissions or 
exacerbations (21).  SPMS onset  was assessed  retrospectively,  at  least  one  
year  after  the  onset  of  the gradual worsening.  
Previous studies have shown that, as an outcome measure, looking at the 
increase in the number of EDSS steps is less dependent on baseline EDSS 
than the more commonly used reaching EDSS 6 (17). Given the long period of 
follow up, we also chose the clinical meaningful endpoints of reaching EDSS 
7.5 and time of conversion to SPMS.In the MRI cohort, due to the shorter 
follow-up time, the endpoint after the first year of treatment was the occurrence 
of sustained EDSS worsening of at least 2 points that was confirmed at the end 
of the follow-up period.  
MRI protocol 
The number of active lesions on the 12-month MRI scan was visually assessed 
by two experienced neuroradiologists who were blinded to the patients’ clinical 
data by direct comparison with the baseline scan, according to previously 
published guidelines (22).  
Statistical analysis 
Descriptive statistics were used to assess the demographic and clinical data. To 
identify differences between groups for each of the clinical activity definitions 
analysed, we used Student’s t-test for continuous variables and the chi-square 
and Fisher’s exact tests for categorical variables. 
We calculated the diagnostic properties (sensitivity, specificity, PPV, NPV, and 
accuracy) to identify patients who reached the pre-defined long-term outcomes. 
The 95% confidence intervals (CIs) of each of these indices for each parameter 
or scoring system were calculated. 
Kaplan-Meier survival analyses were used to estimate the cumulative risk of 
developing endpoints of EDSS worsening according to the presence or absence 
of active disease based on the above-mentioned parameters and score 
systems after the beginning of therapy. We performed uni- and multivariate 
logistic regression and Cox proportional hazards analyses to study the 
prognostic value of early clinical disease activity for the prediction of long-term 
disability outcomes. In these analysis, it has been considered “time zero” the 
beginning of treatment plus 2 years (clinical cohort) or plus 1 year (MRI cohort). 
Statistical analysis was performed with SPSS 20.0 (SPSS Inc., Chicago, IL), 
SAS (SAS Institute Inc., Cary, NC), and G-Stat (GlaxoSmithKline S.A., Spain) 




A total of 516 patients were included in the main analyses; specifically, 283 
formed the clinical and 233 formed the MRI cohort of patients (Figure 2).  
As shown in Figure 2, in the clinical cohort, 234 (83%) patients (163 females, 71 
males) were identified as having at least 12 years of follow-up. The mean 
clinical follow-up in this cohort was 11.5 (SD 3.1) years (range 2-17.3 years). 
There were no significant baseline differences in terms of age, gender, disease 
activity and EDSS between the patients lost to follow-up and those who 
underwent a full assessment (data not shown). Twelve (4%) patients died (5 
patients died due to respiratory infection, 2 patients died due to lung cancer, 
and the other deaths were due to urinary sepsis, a car accident, suicide, 
cerebral haemorrhage, and leukaemia), and 37 (13%) patients were lost to 
follow-up. The mean age in this cohort at treatment onset was 32.7 (SD 9.4) 
years, with a mean disease duration of 6.2 (SD 5.3) years. The mean number of 
relapses in the 2 years before treatment was 2.7 (SD 1.3), and the median 
EDSS score at study entry was 2 (range 0-5.5). In the MRI cohort, 209 (90%) 
patients (152 females, 57 males) were identified as having at least 8 years of 
follow-up. The mean clinical follow-up in this cohort was 6.75 (SD 0.8) years 
(range 1-13.2 years). One (0.5%) patient died due to a pancreatic neoplasm, 
and 12 (5%) were lost to follow-up. The patients had a mean age of 34.2 years 
(SD 9.7; range 18-69) at the beginning of treatment and a mean disease 
duration of 4.7 years (SD 5.4; range 1- 47). The median EDSS score at 
baseline was 2 (range 0-5.5). Patients had a mean number of relapses over the 
previous two years of 1.9 (SD 0.9; range 1-5).  
Early clinical activity and long-term disability in the clinical cohort  
In this cohort, 120 patients (51%) were clinically active during the first 2 years, 
107 (46%) had at least one relapse, 44 (19%) had EDSS worsening, and 31 
(13%) had relapses and EDSS worsening.  
During the follow-up period, 77 (31%) patients had developed SPMS, 62 (25%) 
had an EDSS worsening of at least 5 points, and 39 (16%) had reached an 
EDSS score of 7.5. No patient reached these outcomes during the first 2 years 
of treatment. As shown in figure 3 all studied measures of clinical activity after 
two years of treatment confer a significant risk of achieving the long-term 
outcome. However, it is important to note that the presence of one relapse 
without changes in EDSS during the first two years of treatment did not confer a 
significant risk of developing long-term disability (OR 1.6; 95% CI 0.6-3.8 for 
SPMS and OR 2.2; 95% CI 0.7-6.8 for 5-step EDSS worsening) compared with 
the risk in patients without relapses. 
The sensitivity, specificity, predictive values, and accuracy values for the 
different clinical activity measures at two years used to predict relevant 
outcomes at 12 years are shown in Table 1.  
 
Early clinical and MRI activity and long-term disability in MRI cohort 
In this cohort, 51 patients (23%) had ≥1 relapse, 33 (15%) had at least one 
point of EDSS worsening, 132 (59%) had at least one new T2 lesion and 63 
(28%) had at least one Gd-enhancing lesion on the MRI performed 12 months 
after initiating therapy. One hundred and forty-seven patients (76%) had some 
evidence of disease activity (EDA). During the follow-up period, 44 patients 
(20%) had an EDSS worsening of at least 2 points. No patient reached the 
outcome during the first year of treatment. 
Figure 4 shows the risk of developing an EDSS worsening during the follow-up 
period in patients with clinical or MRI activity in the first year of treatment 
adjusted for age, gender, and baseline EDSS. From a clinical point of view, the 
presence of ≥1 relapse during had a marginal effect on the risk of long-term 
disability (HR 1.5, 95% CI 0.8-2.9). From a MRI perspective, the presence of at 
least 3 new T2 lesions (HR 2.9, 95% CI 1.5-5.6) or of at least 2 Gd-enhancing 
lesions (HR 2.1, 95% CI 1.1-4) was able to identify patients with EDSS 
worsening. In contrast, the presence of MEDA (<3 new T2 lesions or <2 Gd-
enhancing lesions) did not properly identify patients with a risk of EDSS 
worsening. Additionally, MEDA defined by the presence of one relapse with 0 or 
1-2 new T2 lesions had only a marginal effect on the risk of long-term disability 
(HR 2.2, 95% CI 0.7-7.4). However, a RS ≥2 (HR 3.3, 95% CI 1.7-6.4) 
conferred a significant risk of long-term disability. By contrast, neither the MRS 
(0-1 versus 2-3) nor EDA predicted EDSS worsening (figure 5). As shown in 
table 2, EDA and ≥1 new T2 lesion were the most sensitive measures; however, 
both showed the lowest specificity. The combined scores had acceptable 
specificity but poor sensitivity. A RS ≥2 showed the best balance between 
sensitivity and specificity.  
 
Discussion 
Although IFN showed a positive effect, the accumulated data (23, 24) indicate 
that some patients will present long-term disability despite therapy; therefore, 
the early identification of these patients is important to optimize the benefit of 
treatment and to determine the best course of therapy. Our study demonstrates 
that the presence of early significant clinical or MRI activity during treatment 
with IFN is a relevant predictor of the long-term worsening of the disability.  
Although it has been demonstrated that the long-term prognosis could be better 
in treated patients compared with untreated patients (25), there are a lack of 
early predictors of long-term disability in the former group. A study that 
examined the prognosis of pooled patients (2 doses and placebo combined) 
included in the pivotal trial of IFN-1b showed that changes in EDSS (p<0.0001) 
and relapse rate (p<0.025) during the study (0-2 years) were associated with a 
worse prognosis, defined as reaching an EDSS score of 6 or transitioning to 
SPMS after 16 years (26). Another recent study evaluating the 15-year 
prognosis in patients treated with IFN demonstrated that patients with at least 
two relapses during the first two years of therapy had a higher of severe 
disability at 15 years (OR 4.44, CI 1.43-13.85, p<0.01) (15). Similarly, in our 
study, we observed that the presence of relapses or EDSS worsening during 
the first 2 years of therapy had a very negative impact on the long-term 
prognosis.  
Although new T2 lesions during the first 12 months of IFNβ has been 
associated with a poor clinical outcome over 2 years (27) the degree of MRI 
activity that confers a significant risk of EDSS worsening in the long-term has 
not been determined. In a recent systematic review, the presence of one new 
T2 lesion did not show statistical significance in the prediction of treatment 
failure (28). Our data, with a much longer follow-up period, confirmed these 
findings. The presence of 1 or 2 new T2 lesions does not pose a significant risk 
of long-term disability (HR 0.8, 95% IC 0.2-2.7). However, significant MRI 
activity (≥3 new T2 or ≥2 Gd-enhancing lesions) at 12 months clearly predicts a 
poor long-term outcome.  
 
The main relevance of the scoring systems is to facilitate evidence-based and 
quantitative decision-making to determine the best therapeutic approach for a 
given patient (29). In our work, the scores studied show that the combination of 
relapses, sustained disability and new T2/gadolinium lesions (RS ≥2) allow for 
better identification of patients with a worse prognosis (HR 3.3, 95% CI 1.7-6.4). 
Similarly, the MAGNIMS study group, demonstrates that a high increase in the 
risk of progression is present when, after 1 year of IFN-β treatment, there is 1 
relapse and a substantial MRI activity (i.e., ≥3 new T2 lesions) (20). 
NEDA has garnered increasing attention as a measure that may allow for earlier 
and more accurate prognostication and has become a secondary outcome 
measure in clinical trials for new therapies in MS (18). However, in our study 
NEDA did not reach a ststistical significance for predicting outcomes in 
individual patients (HR 1.7; 95% CI 0.8-3.6), although we cannot rule out a lack 
of statistical power due to the sample size. 
Overall, the predictive value of all the studied scores was limited, as the 
observed PPVs did not exceed 50% and the NPVs were lower than 90%. The 
criterion with the best-balanced accuracy was a RS≥2. As has been recently 
described (30), the MRS had the highest specificity (88%) but with a lower 
sensitivity than RS≥2 (19% vs. 40%). However, MRS (a pure activity based 
measure) does not perform as well as the RS – a combination of activity and 
worsening / progression, in predicting future EDSS deterioration (17).  
New drugs are not free of toxicity, nor do they always have complete efficacy, 
thus, their use must be reserved for patients at risk for long-term disability. 
However, we lack data to assure that switching or escalating therapy in this 
group of patients will improve their long-term prognosis. On the other hand, the 
degree of early disease activity that confers a potential risk of a poor long-term 
prognosis is currently unknown. Our results reveal that MEDA (one relapse 
without an impact on disability, the presence of minimal isolated radiological 
activity (one or 2 new T2 lesions or a single Gd-enhancing lesions), or even the 
presence of minimal clinical and radiological activity (1 isolated relapse and 1 
new T2 lesion)), did not confer a significant risk of EDSS worsening during the 
study follow-up.  Data with a longer follow-up (i.e. 15 or 20 years) and larger 
sample are needed in order to clarify this observation.  
Disease duration at treatment initiation in our cohorts are longer than expected 
today, thus, predictions may not be fully useful for patients with CIS or early MS. 
Despite this and other limitations, such as: different treatment strategies during 
follow-up, adherence, presence of neutralizing antibodies, lack of information 
about spinal cord MRI, lack of a control untreated group or the appearance of 
new T2 lesions that could develop in the period between the baseline MRI scan 
and the beginning of the treatment, potentially reducing the predictive power of 
MRI; our study has several strengths. First, because long-term data are so 
critical for obtaining valid and accurate information on a therapeutic effect, we 
used very strict long-term outcomes. Second, the study has been developed in 
a real-life setting and finally, the study had a low rate of patients lost to follow-
up.  
In summary, the data reported in this study reinforce the idea that early 
significant clinical and MRI activity during IFN treatment is associated with a 
poor long-term prognosis. In contrast, in patients with MEDA, a watchful waiting 
period is reasonable before implementing treatment changes. However, these 
findings should be interpreted with caution and need to be confirmed in other 
cohorts and with drugs other than IFN.  
References 
1. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in 
relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, 
randomized, double-blind, placebo-controlled trial. Neurology 1993; 43:655-
661. 
2. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon -1a for 
disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 
39:285-294. 
3. PRISMS Study Group. Randomised double-blind placebo-controlled study of 
interferon -1a in relapsing-remitting multiple sclerosis. Lancet 1998; 
352:1498-1504. 
4. Paty DW, Li DK, for the University of British Columbia MS/MRI Study Group 
and the IFN Multiple Sclerosis Study Group. Interferon beta-1b is effective 
in relapsing-remitting multiple sclerosis. II. MRI analysis results of a 
multicenter, randomized, double-blind, placebo-controlled trial. Neurology 
1993; 43: 662-667. 
5. Simon JH, Jacobs LD, Campion M, et al, for the Multiple Sclerosis 
Collaborative Research Group. Magnetic Resonance studies of 
intramuscular interferon -1a for the relapsing multiple sclerosis. Ann Neurol 
1998; 43: 79-87. 
6. Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: A 
randomized, double-blind, placebo-controlled study of interferon-1a in 
relapsing-remitting multiple sclerosis. Ann Neurol 1999; 46: 197-206.  
7. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational 
studies and the hierarchy of research designs.N Engl J Med 
2000;342:1887–1892. 
8. Río J, Comabella M, Montalban X. Predicting responders to therapies for 
multiple sclerosis. Nat Rev Neurol. 2009; 5:553-560. 
9. Rudick RA, Polman CH. Current approaches to the identification and 
management of breakthrough disease in patients with multiple sclerosis. 
Lancet Neurol 2009; 8:545-559. 
10. Rudick R, Lee J, Simon J, et al. Defining interferon  response status in 
multiple sclerosis patients. Ann Neurol 2004; 56: 548-555. 
11. Prosperini L, Gallo V, Petsas N, et al. One-year MRI scans predicts clinical 
response to interferon beta in multiple sclerosis. Eur J Neurol 2009; 16: 
1202-1209. 
12. Rio J, Castillo J, Rovira A, et al. Measures in the first year of therapy predict 
the response to interferon beta in MS. Mult Scler 2009; 15: 848-853    
13. Sormani MP, Rio J, Tintore M et al. Scoring treatment response in patients 
with relapsing multiple sclerosis. Mult Scler 2013; 19:605-612. 
14. Prosperini L, Mancinelli CR, De Giglio L, et al. Interferon beta failure 
predicted by EMA criteria or isolated MRI activity in multiple sclerosis. Mult 
Scler 2014; 20: 566-576 
15. Bermel RA, You X, Foulds P, et al. Predictors of long-term outcome in 
multiple sclerosis patients treated with interferon beta. Ann Neurol 2013; 
73:95-103. 
16. Uher T, Vaneckova M, Sobisek L, et al. Combining clinical and magnetic 
resonance imaging markers enhances prediction of 12-year disability in 
multiple sclerosis. Mult Scler. 2016 Apr 6. pii: 1352458516642314. 
17. Rio J, Nos C, Tintoré M, et al. Defining the response to interferon-beta in 
relapsing-remitting multiple sclerosis patients. Ann Neurol 2006; 59: 344-
352. 
18. Rotstein DL, Healy BC, Malik MT, et al. Evaluation of no evidence of disease 
activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol 2015; 
72:152-158. 
19. Grand'Maison F, Bhan V, Freedman MS, et al. Utility of the Canadian 
Treatment Optimization Recommendations (TOR) in MS care Can J Neurol 
Sci 2013; 40, 527–535  
20. Sormani MP, Gasperini C, Romeo M, et al. Assessing response to 
interferon-β in a multicenter dataset of patients with MS. Neurology. 2016 Jul 
12;87(2):134-40.. 
21. Kremenchutzky M, Cottrell D, Rice G, et al. The natural history of multiple 
sclerosis: a geographically based study. 7. Progressive-relapsing and 
relapsing-progressive multiple sclerosis: a re-evaluation. Brain 1999; 
122:1941-1950. 
22. Molyneux, PD, Miller, DH, Filippi, M, et al. Visual analysis of serial T2-
weighted MRI in multiple sclerosis: intra and interobserver reproducibility. 
Neuroradiology 1999; 41: 882–888. 
23. Goodin DS, Reder AT, Ebers GC, et al. Survival in MS: a randomized cohort 
study 21 years after the start of the pivotal IFNB-1b trial. Neurology 
2012;78:1315–1322. 
24. Bermel RA, Weinstock-Guttman B, Bourdette D, et al. Intramuscular 
interferon beta-1a therapy in patients with relapsing-remitting multiple 
sclerosis: a 15-year follow-up study. Mult Scler 2010;16:588–596. 
25. Trojano M, Pellegrini F, Fuiani A, et al. New natural history of interferon-
beta-treated relapsing multiple sclerosis. Ann Neurol 2007; 61: 300-306. 
26. Goodin DS, Traboulsee A, Knappertz V, et al. Relationship between early 
clinical characteristics and long term disability outcomes: 16 year cohort 
study (follow-up) of the pivotal interferón beta-1b trial in multiple sclerosis. J 
Neurol Neurosurg Psychiatry 2012;83:282–287. 
27. Río J, Rovira A, Tintoré M, et al. Relationship between MRI lesion activity 
and response to IFN-beta in relapsing–remitting multiple sclerosis patients. 
Mult Scler 2008; 14: 479–484. 
28. Dobson R, Rudick RA, Turner B, et al. Assessing treatment response to 
interferon-β: is there a role for MRI? Neurology 2014;82:248-254. 
29.  Sormani, MP, De Stefano N. Defining and scoring response to IFN-β in 
multiple sclerosis. Nat. Rev. Neurol, 2013; 9: 504–512 
30. Romeo M, Martinelli V, Rodegher M, et al. Validation of 1-year predictive 
score of long-term response to interferon-β in everyday clinical 










Figure 1. Cohorts and study design. 
 
Figure 2. Flowchart of the patients included in the study. 
a. As per Rio et al. Ann Neurol 2006 (16) 
b. As per Rio et al. Mult Scler 2009 (12) 
 
Figure 3. Effect of early clinical activity on the development of long-term 
disability.  
CI: Confidence interval 
HR: Hazard ratio 
OR: Odds ratio 
a. No relapses as the reference category 
b. No relapses and <1 EDSS point as the reference category 
 
 
Figure 4. Effect of early clinical and radiological activity on the development of 
long-term disability. 
CI: Confidence interval 
a. No relapses as the reference category 
b. No new T2 or Gd lesions as the reference category 
c. No relapses and no new T2 or Gd lesions as the reference category 
d. RS or MRS <2 as the reference category 
e. NEDA as the reference category 
 
 
Figure 5. Kaplan-Meier curves showing the cumulative probability of EDSS 
worsening ≥2 points according to the different scoring systems during the 
follow-up period. 
a. Rio score  
b. Modified Rio score 
c. Evidence of disease activity 
 
